A novel electrochemical analysis of the legal psychoactive drug caffeine using a zeolite/MWCNT modified carbon paste sensor

2019 ◽  
Vol 43 (38) ◽  
pp. 15359-15367 ◽  
Author(s):  
Shereen M. Azab ◽  
M. Shehata ◽  
Amany M. Fekry
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Electrochemical Analysis ◽  
Psychoactive Drug ◽  
Carbon Paste ◽  
Maximal Amount ◽  
Central Nervous System Stimulant ◽  
The Us

Caffeine (Caf) is a natural central nervous system stimulant categorized by the US Food and Drug Administration as a safe drug and its maximal amount in soft drinks has been approximately determined to be lower than 200 mg L−1.

Recent Advances in Pharmacotherapy

2009 ◽  
Vol 22 (5) ◽  
pp. 446-466
Author(s):  
Debra W. Kemp ◽  
Jamie N. Brown ◽  
Toyin S. Tofade
Keyword(s):  
Internal Medicine ◽  
Central Nervous System ◽  
Nervous System ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Metabolic Function ◽  
Body System ◽  
Immunological Function ◽  
Drug Reactions ◽  
New Treatments

Many unique and clinically important medications were approved by the Food and Drug Administration from December 2007 through May 2008 for various conditions encountered in an internal medicine setting. These new treatments dramatically vary in their targeted body system and include agents for the cardiovascular system (nebivolol), central nervous system (desvenlafaxine), gastrointestinal tract (certolizumab, methylnaltrexone, and alvimopan), immunological function (etravirine), and metabolic function (sapropterin). This article discusses medications by their respective body system. Each review is comprised of an overview of the Food and Drug Administration–approved indication and the drug’s role in treatment of that disease state. Current dosing guidance, clinical efficacy and clinically relevant adverse drug reactions, drug interactions, contraindications, and precautions are also presented. This review is designed to focus on the new molecular entities and biological approvals clinicians may potentially encounter in an internal medicine practice.

scholarly journals 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

2021 ◽  
Vol 14 (2) ◽  
pp. 145
Author(s):  
Othman Al Musaimi ◽  
Danah Al Shaer ◽  
Fernando Albericio ◽  
Beatriz de la Torre
Keyword(s):  
Adverse Effects ◽  
Global Health ◽  
Drug Administration ◽  
Mode Of Action ◽  
Chemical Structure ◽  
Food And Drug Administration ◽  
Health Crisis ◽  
New Drug ◽  
Target Mode ◽  
The Us

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

Sign in / Sign up

Export Citation Format

Share Document